Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

Vaxcyte Inc. shares surge as positive vaccine pipeline news boosts investor optimism, with stocks have been trading up by 58.09 percent. Key Takeaways BofA trimmed its PCVX price target to $130 from $133 but kept a Buy rating and a 75% success probability for VAX-31 into the pivotal OPUS-1 readout.

Vaxcyte Inc. stocks have been trading up by 56.14 percent, driven mainly by strong vaccine pipeline progress and investor optimism. Key Takeaways BofA slightly reduced its price target on Vaxcyte from $133 to $130 but reaffirmed a Buy rating, assigning a 75% probability of clinical success for VAX-31 and calling the Phase 3 OPUS-1 readout…

Vaxcyte Inc. stocks have been trading up by 52.09 percent, driven primarily by strong clinical progress and regulatory momentum. Key Takeaways BofA slightly trimmed its PCVX price target from $133 to $130 but reaffirmed a Buy rating and a 75% success probability for the pivotal OPUS-1 Phase 3

OPUS-1 met the primary noninferiority test on 28 shared serotypes; Vaxcyte expects two more adult trial readouts in first half 2027.

Vaxcyte Inc. shares surge as positive vaccine pipeline news boosts investor optimism, with stocks have been trading up by 58.09 percent. Key Takeaways BofA trimmed its PCVX price target to $130 from $133 but kept a Buy rating and a 75% success probability for VAX-31 into the pivotal OPUS-1 readout.